[◀返回](./home.md)

# 灵性增强 (Spirituality intensification)

**灵性增强**是指一个人的个人信仰发生转变的体验，这种转变关于他们的存在、他们在宇宙中的位置、与他人的关系，以及他们认为生命中有意义的东西。这会导致一个人重新思考他们对某些关键概念的重视程度，比以前更看重某些概念，而认为其他概念不那么重要了呢。[1] 这些概念和观念不限于此，但一般包括这些喵：

*   个人使命感的增强。[2]
*   对追求发展个人宗教和精神意识形态的兴趣增加。[3][4]
    *   形成复杂的个人宗教信仰。
*   对自然和他人的同情心增强。[3][4][5]
*   自身、自然、“神”和整个宇宙之间的[统一感与相互连接感](/药效/统一感与相互连接感.md)增强。[1][3][5][6][7][8][9]
*   对金钱和物质的重视程度降低。[5]
*   对死亡和存在的有限性的恐惧减少，接受度提高。[1][10][11]

虽然因为灵性增强的主观性，很难完全讲清楚，但这些信仰体系的改变通常会导致一个人性格的深刻变化喵，[5][7][12] 这种变化有时对他身边的人来说是非常明显的。这种转变可能会突然发生，但通常随着一个人重复使用诱发这种转变的[精神活性物质](/文档/精神活性物质.md)而逐渐增加。

灵性增强不太可能是一个孤立的效应，而是在适当的[情景与心境](/文档/情景与心境.md)下，结合其他伴随效应的结果，[3] 比如[分析能力增强](/药效/分析能力增强.md)、[自主声音交流](/药效/自主声音交流.md)、[新奇感增强](/药效/新奇感增强.md)、[对立统一感知](/药效/对立统一感知.md)、[宿命论感知](/药效/宿命论感知.md)、[自我设计感](/药效/自我设计感.md)、[个人偏见抑制](/药效/个人偏见抑制.md)和[统一感与相互连接感](/药效/统一感与相互连接感.md)。它最常在[中等](/文档/给药剂量.md#中等)[剂量](/文档/给药剂量.md)的[致幻剂](/文档/药物分类/致幻剂.md)类化合物影响下产生，比如[LSD](/药物/LSD.md)、[赛洛西宾](/药物/赛洛西宾蘑菇.md)和[麦斯卡林](/药物/麦斯卡林.md)。不过呢，在[解离剂](/文档/药物分类/解离剂.md)的影响下，如[氯胺酮](/药物/氯胺酮.md)、[PCP](/药物/PCP.md)和[右美沙芬](/药物/右美沙芬.md)，也会发生程度较轻的这种情况哦。

## 内容
*   [1 分析](#分析)
*   [2 精神活性物质](#精神活性物质)
*   [3 体验报告](#体验报告)
*   [4 另见](#另见)
*   [5 外部链接](#外部链接)
*   [6 参考文献](#参考文献)

### 分析

有许多深入的科学研究一致支持[致幻剂](/文档/药物分类/致幻剂.md)使用所诱发的精神效应是真实存在的喵。[1][3][4][5][6][7][8][9][12][13][14][15][16][17][18][19]

通常，新的[迷幻剂](/文档/药物分类/迷幻剂.md)使用者会将他们的体验评为一生中最有意义的单一体验，或者是前五名最有意义的体验之一呢。[4][6][10][12]

任何有意用于宗教或精神目的的[迷幻剂](/文档/药物分类/迷幻剂.md)或[致幻剂](/文档/药物分类/致幻剂.md)在文献中被称为[神圣致幻剂](/文档/神圣致幻剂.md)（Entheogen）。[3][20] 为了宗教或精神目的而仪式性地使用[神圣致幻剂](/文档/神圣致幻剂.md)可以追溯到几千年前，并且在人类学和现代证据中都得到了很好的证实哦。[3][4][5][12][15][17][21][22][23][24][25][26][27]

<!-- 请勿删除或修改，这是一个标记，待识别并填坑（药效索引） -->

### 体验报告

在我们的[体验索引](/文档/体验索引.md)中描述这种效应的轶事报告包括：

*   [Experience: 1 tab 1P-LSD (oral) - Finding myself within the forest](/报告/psychounautwiki/Experience:_1_tab_1P-LSD_(oral)_-_Finding_myself_within_the_forest)
*   [Experience: 22mg 2C-B (oral) / 100ug 1P-LSD (sublingual) - My first time tripping alone (2 days in a row)](/报告/psychounautwiki/Experience:_22mg_2C-B_(oral)_/_100ug_1P-LSD_(sublingual)_-_My_first_time_tripping_alone_(2_days_in_a_row))
*   [Experience:1.5 Grams Psilocybe Cubensis](/报告/psychounautwiki/Experience:1.5_Grams_Psilocybe_Cubensis)
*   [Experience:10mg & 20mg Intravenous DPT HCl - Familiar Shapes, Experiencing Death, Immersed in The Light](/报告/psychounautwiki/Experience:10mg_%26_20mg_Intravenous_DPT_HCl_-_Familiar_Shapes,_Experiencing_Death,_Immersed_in_The_Light)
*   [Experience:2 grams Psilocybe Cubensis + 2.7 grams Syrian Rue - The Psilohuasca Albino Fox](/报告/psychounautwiki/Experience:2_grams_Psilocybe_Cubensis_%2B_2.7_grams_Syrian_Rue_-_The_Psilohuasca_Albino_Fox)
*   [Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective](/报告/psychounautwiki/Experience:3_Grams_of_Mushrooms_-_Reset_on_my_Life,_Experiencing_Satori_and_the_Cosmic_Perspective)
*   [Experience:300ug LSD - Profound religious experience](/报告/psychounautwiki/Experience:300ug_LSD_-_Profound_religious_experience)
*   [Experience:30mg (smoked) DMT - The Monolith](/报告/psychounautwiki/Experience:30mg_(smoked)_DMT_-_The_Monolith)
*   [Experience:400ug LSD + weed + nitrous -- Fundamental insights into the universe](/报告/psychounautwiki/Experience:400ug_LSD_%2B_weed_%2B_nitrous_--_Fundamental_insights_into_the_universe)
*   [Experience:40mg + Syrian Rue (unknown dosage) - My one bad trip](/报告/psychounautwiki/Experience:40mg_%2B_Syrian_Rue_(unknown_dosage)_-_My_one_bad_trip)
*   [Experience:60mg 4-AcO-DMT Nonstop Quasi-Orgasmic Objectless Euphoria](/报告/psychounautwiki/Experience:60mg_4-AcO-DMT_Nonstop_Quasi-Orgasmic_Objectless_Euphoria)
*   [Experience:LSA (20 HWBR seeds) – A pleasant adventure with a harsh body load](/报告/psychounautwiki/Experience:LSA_(20_HWBR_seeds)_%E2%80%93_A_pleasant_adventure_with_a_harsh_body_load)
*   [Experience:LSD (150µg) + Cannabis - 150µg lsd and a shitload of weed](/报告/psychounautwiki/Experience:LSD_(150%C2%B5g)_%2B_Cannabis_-_150%C2%B5g_lsd_and_a_shitload_of_weed)
*   [Experience:LSD (230 ug) - An amazing adventure by vikilikepsych](/报告/psychounautwiki/Experience:LSD_(230_ug)_-_An_amazing_adventure_by_vikilikepsych)
*   [Experience:LSD (400ug, Oral) - An afternoon in "a" garden](/报告/psychounautwiki/Experience:LSD_(400ug,_Oral)_-_An_afternoon_in_%22a%22_garden)
*   [Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)](/报告/psychounautwiki/Experience:Mushrooms_and_Snuff_Films_--_Trip_Report_(3.5_grams))
*   [Experience:Unknown dosage / 1 tabs - Prolonged unity and messiah syndrome at school](/报告/psychounautwiki/Experience:Unknown_dosage_/_1_tabs_-_Prolonged_unity_and_messiah_syndrome_at_school)

### 另见

*   [负责任的用药](/文档/负责任的用药索引页.md)
*   [主观效应索引](/文档/主观效应索引.md)
*   [迷幻剂 - 主观效应](/文档/药物分类/迷幻剂.md#主观效应)
*   [解离剂 - 主观效应](/文档/药物分类/解离剂.md#主观效应)
*   [谵妄剂 - 主观效应](/文档/药物分类/谵妄剂.md#主观效应)

### 外部链接

*   [神经神学 (Wikipedia)](https://en.wikipedia.org/wiki/Neurotheology)
*   [灵性 (Wikipedia)](https://en.wikipedia.org/wiki/Spirituality)

### 参考文献

*(此处保留原文参考文献链接，因不涉及PsychonautWiki内链)*
1. 1.0 1.1 1.2 1.3 Gasser, P., Kirchner, K., Passie, T. (January 2015). "LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects". Journal of Psychopharmacology. 29 (1): 57–68.
2. Peterman, A. H., Fitchett, G., Brady, M. J., Hernandez, L., Cella, D. (February 2002). "Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp)". Annals of Behavioral Medicine. 24 (1): 49–58.
3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Trichter, S., Klimo, J., Krippner, S. (June 2009). "Changes in Spirituality Among Ayahuasca Ceremony Novice Participants". Journal of Psychoactive Drugs. 41 (2): 121–134.
4. 4.0 4.1 4.2 4.3 4.4 Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., Jesse, R. (December 2011). "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects". Psychopharmacology. 218 (4): 649–665.
5. 5.0 5.1 5.2 5.3 5.4 5.5 Lerner, M., Lyvers, M. (June 2006). "Values and Beliefs of Psychedelic Drug Users: A Cross-Cultural Study". Journal of Psychoactive Drugs. 38 (2): 143–147.
6. 6.0 6.1 6.2 Griffiths, R. R., Richards, W. A., McCann, U., Jesse, R. (August 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283.
7. 7.0 7.1 7.2 MacLean, K. A., Johnson, M. W., Griffiths, R. R. (November 2011). "Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness". Journal of Psychopharmacology. 25 (11): 1453–1461.
8. 8.0 8.1 Kometer, M., Pokorny, T., Seifritz, E., Volleinweider, F. X. (October 2015). "Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations". Psychopharmacology. 232 (19): 3663–3676.
9. 9.0 9.1 Lyvers, M., Meester, M. (1 November 2012). "Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner". Journal of Psychoactive Drugs. 44 (5): 410–417.
10. 10.0 10.1 Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., Schmidt, B. L. (December 2016). "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial". Journal of Psychopharmacology. 30 (12): 1165–1180.
11. Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., Greer, G. R. (3 January 2011). "Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer". Archives of General Psychiatry. 68 (1): 71.
12. 12.0 12.1 12.2 12.3 Studerus, E., Kometer, M., Hasler, F., Vollenweider, F. X. (November 2011). "Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies". Journal of Psychopharmacology. 25 (11): 1434–1452.
13. Cummins, C., Lyke, J. (April 2013). "Peak Experiences of Psilocybin Users and Non-Users". Journal of Psychoactive Drugs. 45 (2): 189–194.
14. Griffiths, R., Richards, W., Johnson, M., McCann, U., Jesse, R. (August 2008). "Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later". Journal of Psychopharmacology. 22 (6): 621–632.
15. 15.0 15.1 Bakalar, J. B. (October 1985). "Social and Intellectual Attitudes Toward Drug-Induced Religious Experience". Journal of Humanistic Psychology. 25 (4): 45–66.
16. Móró, L., Simon, K., Bárd, I., Rácz, J. (July 2011). "Voice of the Psychonauts: Coping, Life Purpose, and Spirituality in Psychedelic Drug Users". Journal of Psychoactive Drugs. 43 (3): 188–198.
17. 17.0 17.1 Nichols, D. E. (April 2016). Barker, E. L., ed. "Psychedelics". Pharmacological Reviews. 68 (2): 264–355.
18. Luke, D. (1 January 2012). "Psychoactive Substances and Paranormal Phenomena: A Comprehensive Review". International Journal of Transpersonal Studies. 31 (1): 97–156.
19. Luke, D., Kittenis, M. (2005). "A preliminary survey of paranormal experiences with psychoactive drugs" (PDF). Journal of Parapsychology. 69: 305–327.
20. Ruck, C. A. P., Bigwood, J., Staples, D., Ott, J., Wasson, R. G. (January 1979). "Entheogens". Journal of Psychedelic Drugs. 11 (1–2): 145–146.
21. Guzmán, G. (November 2008). "Hallucinogenic Mushrooms in Mexico: An Overview". Economic Botany. 62 (3): 404–412.
22. Bruhn, J. G., De Smet, P. A., El-Seedi, H. R., Beck, O. (May 2002). "Mescaline use for 5700 years". The Lancet. 359 (9320): 1866.
23. El-Seedi, H. R., Smet, P. A. G. M. D., Beck, O., Possnert, G., Bruhn, J. G. (October 2005). "Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas". Journal of Ethnopharmacology. 101 (1–3): 238–242.
24. Pettigrew, J. (1 September 2011). "Iconography in Bradshawb rock art: breaking the circularity". Clinical and Experimental Optometry. 94 (5): 403–417.
25. Carod-Artal, F. J. (January 2015). "Alucinógenos en las culturas precolombinas mesoamericanas". Neurología. 30 (1): 42–49.
26. Wasson, R. G. (April 1971). "The Soma of the Rig Veda: What Was It?". Journal of the American Oriental Society. 91 (2): 169.
27. Rios, M. D. de (July 1977). "Hallucinogenic Ritual as Theatre". Journal of Psychedelic Drugs. 9 (3): 265–268.